ADPT · Healthcare
Adaptive Biotechnologies Corp
26/100
Smart-money confidence1 of 3 sources positive
Below average interest
company insiders are selling
What this band has actually done: stocks scoring 0–25 beat the S&P 500 over the next three months 39.9% of the time, across 100,496 cases since 2015. That is below a coin flip — and so is every other band, because the median stock loses to a cap-weighted index. How we measured this
Hedge funds
51
Congress
No data
Insiders
0
Cross-source blend of hedge-fund breadth, Congress trades, and insider Form 4s. ·
how the score works
Market cap
$4.7B
Industry
Diagnostics & Research
Sector
Healthcare
Exchange
NasdaqGS
About ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers…
Who's behind the signal
Every informed buyer we can see on ADPT, across all three feeds.
Hedge funds · 10
D.E. Shaw & Co
Increased +135%
Renaissance Technologies
Increased +26%
Viking Global Investors
Unchanged
ARK Invest (Cathie Wood)
Unchanged
Tudor Investment (Paul Tudor Jones)
Decreased −31%
Millennium Management (Englander)
Decreased −53%
+4 more in the full breakdown below ↓
Congress · 0
No congressional trades on record.
Insiders
Company insiders
Selling
Recent sells25
Not a model pick — but on our radar.
ADAPTIVE BIOTECHNOLOGIES CORP isn't in the top-10 model right now, but 10 tracked investors hold it. Everything below is real signal from public filings — treat this as a watch candidate, not a conviction call.
10
Investors
0
New positions
2
Increasing
6
Decreasing
2
Unchanged
Price History
Loading price data...
Return:
High:
Low:
Who's Holding This Stock
Position sizes and recent activity from tracked institutional investors
Trust weight: 1.0×
% of portfolio
0.1%
Position change
+135%
0.1% of D.E. Shaw & Co's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
+26%
0.0% of Renaissance Technologies's portfolio
Trust weight: 1.5×
% of portfolio
1.8%
Position change
—
1.8% of Viking Global Investors's portfolio
Trust weight: 1.3×
% of portfolio
0.3%
Position change
—
0.3% of ARK Invest's portfolio
Trust weight: 1.2×
% of portfolio
0.1%
Position change
−31%
0.1% of Tudor Investment's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
−53%
0.0% of Millennium Management's portfolio
Trust weight: 1.1×
% of portfolio
0.0%
Position change
−18%
0.0% of Gotham Asset Mgmt's portfolio
Trust weight: 1.3×
% of portfolio
0.0%
Position change
−55%
0.0% of Bridgewater Associates's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
−50%
0.0% of Citadel Advisors's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
−25%
0.0% of AQR Capital Management's portfolio
Portfolio Allocation
How much of each investor's portfolio is allocated to ADAPTIVE BIOTECHNOLOGIES CORP
Insider Trading (Form 4)
Recent trades by company officers and directors — filed within 2 days of each trade
Bearish
Sentiment
0
Buys
25
Sells
| Date | Insider | Title | Action | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-09-16 | LO FRANCIS | Insider | SELL | 7,869 | $28.57 | $224,817 |
| 2026-09-16 | LO FRANCIS | Insider | SELL | 107,537 | $28.02 | $3,013,187 |
| 2026-09-15 | BOBULSKY SUSAN | Insider | SELL | 1,195 | $27.00 | $32,265 |
| 2026-08-26 | OWEN KATEY EINTERZ | Insider | SELL | 9,615 | $26.00 | $249,990 |
| 2026-08-18 | ROBINS CHAD M | Insider | SELL | 204 | $25.14 | $5,129 |
| 2026-08-18 | ROBINS CHAD M | Insider | SELL | 278,472 | $24.48 | $6,816,995 |
| 2026-08-18 | HERSHBERG ROBERT | Insider | SELL | 15,664 | $24.41 | $382,358 |
| 2026-08-18 | HERSHBERG ROBERT | Insider | SELL | 15,000 | $24.39 | $365,850 |
| 2026-08-17 | ROBINS CHAD M | Insider | SELL | 2,525 | $25.57 | $64,564 |
| 2026-08-17 | ROBINS CHAD M | Insider | SELL | 318,799 | $25.08 | $7,995,479 |
| 2026-08-17 | NEUPERT PETER M | Insider | SELL | 69,690 | $25.16 | $1,753,400 |
| 2026-08-17 | NEUPERT PETER M | Insider | SELL | 40,000 | $25.10 | $1,004,000 |
| 2026-08-17 | NEUPERT PETER M | Insider | SELL | 15,000 | $25.23 | $378,450 |
| 2026-08-10 | BOBULSKY SUSAN | Insider | SELL | 3,000 | $25.00 | $75,000 |
| 2026-07-30 | BOBULSKY SUSAN | Insider | SELL | 1,299 | $24.00 | $31,176 |
| 2026-07-21 | ROBINS HARLAN S | Insider | SELL | 213,702 | $22.12 | $4,727,088 |
| 2026-07-21 | ROBINS HARLAN S | Insider | SELL | 278,698 | $21.72 | $6,053,321 |
| 2026-07-16 | BOBULSKY SUSAN | Insider | SELL | 5,000 | $23.00 | $115,000 |
| 2026-07-15 | LO FRANCIS | Insider | SELL | 105,762 | $22.59 | $2,389,164 |
| 2026-07-02 | ROBINS HARLAN S | Insider | SELL | 146,889 | $22.45 | $3,297,658 |
Showing the 20 most recent of 25 buys & sells.
⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell ADAPTIVE BIOTECHNOLOGIES CORP or any security.
Get the Weekly Update
Every week, we'll send you what Buffett, Dalio, Ackman and 47 other legendary investors are buying — free, straight from their SEC filings.
Free forever · No spam · Unsubscribe anytime